- Home
- TYRA vs REAL Comparison
TYRA vs REAL Comparison
Compare TYRA & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- REAL
- Stock Information
- Founded
- TYRA 2018
- REAL 2011
- Country
- TYRA United States
- REAL United States
- Employees
- TYRA N/A
- REAL N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- TYRA Health Care
- REAL Consumer Discretionary
- Exchange
- TYRA Nasdaq
- REAL Nasdaq
- Market Cap
- TYRA 576.6M
- REAL 641.9M
- IPO Year
- TYRA 2021
- REAL 2019
- Fundamental
- Price
- TYRA $9.52
- REAL $5.32
- Analyst Decision
- TYRA Strong Buy
- REAL Buy
- Analyst Count
- TYRA 7
- REAL 5
- Target Price
- TYRA $30.86
- REAL $8.40
- AVG Volume (30 Days)
- TYRA 298.0K
- REAL 4.5M
- Earning Date
- TYRA 05-08-2025
- REAL 05-08-2025
- Dividend Yield
- TYRA N/A
- REAL N/A
- EPS Growth
- TYRA N/A
- REAL N/A
- EPS
- TYRA N/A
- REAL N/A
- Revenue
- TYRA N/A
- REAL $616,717,000.00
- Revenue This Year
- TYRA N/A
- REAL $11.45
- Revenue Next Year
- TYRA N/A
- REAL $10.09
- P/E Ratio
- TYRA N/A
- REAL N/A
- Revenue Growth
- TYRA N/A
- REAL 11.89
- 52 Week Low
- TYRA $6.42
- REAL $2.24
- 52 Week High
- TYRA $29.60
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- TYRA 45.60
- REAL 46.32
- Support Level
- TYRA $8.88
- REAL $4.98
- Resistance Level
- TYRA $9.68
- REAL $5.82
- Average True Range (ATR)
- TYRA 0.64
- REAL 0.33
- MACD
- TYRA -0.08
- REAL -0.00
- Stochastic Oscillator
- TYRA 26.98
- REAL 38.38
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.